These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2655098)

  • 1. Carboplatin in refractory epithelial ovarian cancer.
    Kavanagh JJ; Nicaise C
    Semin Oncol; 1989 Apr; 16(2 Suppl 5):45-8. PubMed ID: 2655098
    [No Abstract]   [Full Text] [Related]  

  • 2. Carboplatin.
    Med Lett Drugs Ther; 1989 Sep; 31(800):83-4. PubMed ID: 2671623
    [No Abstract]   [Full Text] [Related]  

  • 3. Carboplatin versus cisplatin.
    Tighe M; Goodman S
    Lancet; 1988 Dec; 2(8624):1372-3. PubMed ID: 2904096
    [No Abstract]   [Full Text] [Related]  

  • 4. Carboplatin substitution for cisplatin in the treatment of ovarian carcinoma--a word of caution.
    McGuire WP; Abeloff MD
    J Natl Cancer Inst; 1989 Oct; 81(19):1438-9. PubMed ID: 2674458
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparing cisplatin and carboplatin.
    Neijt JP; van Houwelingen JC
    J Natl Cancer Inst; 1990 Mar; 82(5):434-5. PubMed ID: 2406453
    [No Abstract]   [Full Text] [Related]  

  • 6. Treating ovarian cancer.
    Sweetenham JW; Mead GM; Whitehouse JM; Williams CJ
    Br Med J (Clin Res Ed); 1986 Nov; 293(6559):1435-6. PubMed ID: 3099901
    [No Abstract]   [Full Text] [Related]  

  • 7. Whither carboplatin.
    J Clin Oncol; 1987 Jun; 5(6):984-6. PubMed ID: 3295133
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease.
    Lund B; Hansen M; Hansen OP; Hansen HH
    J Clin Oncol; 1989 Oct; 7(10):1469-73. PubMed ID: 2674334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.
    Gore ME; Fryatt I; Wiltshaw E; Dawson T
    Gynecol Oncol; 1990 Feb; 36(2):207-11. PubMed ID: 2404837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
    Abou-Jawde RM; Oberoi SS
    J Clin Oncol; 2008 May; 26(15):2602-3; author reply 2603. PubMed ID: 18487582
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
    Reed E; Ostchega Y; Steinberg SM; Yuspa SH; Young RC; Ozols RF; Poirier MC
    Cancer Res; 1990 Apr; 50(8):2256-60. PubMed ID: 2180564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.
    Weiss G; Green S; Alberts DS; Thigpen JT; Hines HE; Hanson K; Pierce HI; Baker LH; Goodwin JW
    Eur J Cancer; 1991; 27(2):135-8. PubMed ID: 1827275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JM8 (cisplatin analogue) alone for previously untreated advanced ovarian carcinoma.
    Neijt JP; Nortier JW; Vendrik CP; Struyvenberg A
    Lancet; 1983 May; 1(8333):1109-10. PubMed ID: 6133142
    [No Abstract]   [Full Text] [Related]  

  • 14. "Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?
    Markman M
    Gynecol Oncol; 1998 May; 69(2):91-2. PubMed ID: 9600812
    [No Abstract]   [Full Text] [Related]  

  • 15. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.
    Speyer JL; Beller U; Colombo N; Sorich J; Wernz JC; Hochster H; Green M; Porges R; Muggia FM; Canetta R
    J Clin Oncol; 1990 Aug; 8(8):1335-41. PubMed ID: 2199620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ovarian cancer--therapeutic options after the failure of the first line of treatment].
    Jabłońska E; Chłosta M; Pawlega J
    Ginekol Pol; 2004 Jan; 75(1):58-64. PubMed ID: 15112475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CA125 in ovarian tumour tissue at second laparotomy.
    Maughan TS; Fish RG; Shelley MD; Jasani B; Williams GT; Adams M
    Br J Cancer; 1989 Feb; 59(2):259-60. PubMed ID: 2649131
    [No Abstract]   [Full Text] [Related]  

  • 18. New drugs and experimental approaches in ovarian cancer treatment.
    Thigpen JT; Vance RB; Balducci L; Khansur T
    Semin Oncol; 1984 Sep; 11(3):314-26. PubMed ID: 6435251
    [No Abstract]   [Full Text] [Related]  

  • 19. Carboplatin in the first-line chemotherapy of ovarian cancer.
    Alberts DS; Canetta R; Mason-Liddil N
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):54-60. PubMed ID: 2406922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 1997 Jun; 65(3):434-6. PubMed ID: 9190971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.